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Summary
Introduction:  Escherichia  coli  producing  extended  spectrum--lactamases  (ESBL),
particularly  CTX-M  type  ESBLs,  have  rapidly  spread  worldwide  and  pose  a  serious
threat  for  healthcare-associated  infections.  We  performed  a molecular  detection
and  characterization  study  of  ESBL-related  bla  genes,  including  blaTEM,  blaSHV,
blaCTX-M,  and  blaCTX-M15, and  also  assessed  the  relationship  between  the  phylogenetic
background  of  strains  carrying  ESBL  genes  and  the  patient’s  clinical  outcome.
Methodology:  A  total  of  300  non-repeated,  clinically  signiﬁcant  isolates  were  inves-
tigated.  The  molecular  types  of  ESBL  genes  were  determined  using  multiplex  PCR.
Phylogenetic  analysis  was  performed  using  triplex  PCR  methods.  Antibiograms  and
the  patient’s  clinical  outcome  were  collected  in  a  structured  pro  forma.
Results:  Among  the  300  isolates,  212  (70.5%)  isolates  were  found  to  carry  ESBL  genes.
A  total  of  186  (62%)  strains  were  positive  for  the  blaCTX-M gene,  and  171  isolates
(approximately  92%)  of  these  blaCTX-M producers  were  positive  for  blaCTXM-15.  Phylo-
genetic  analysis  of  the  isolates  indicated  that  41  (67%)  Group  A,  22  (81.50%)  group
B1,  67  (64.5%)  group  B2  and  82  (76%)  group  D  isolates  carried  different  ESBL  genes.
Appropriate  antibiotic  therapy  helped  to  resolve  infection  in  66.5%  patients.
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xtra-intestinal  infections  (EIs)  due  to  E.  coli
re common  in  all  age  groups  and  can  involve
early any  organ  or  anatomical  site  [1].  High  lev-
ls of  drug  resistance  among  such  extra-intestinal
. coli  strains  have  now  been  reported  in  India.
uch extended-spectrum  -lactamase  (ESBL)  pro-
ucers have  rapidly  spread,  and  at  present,
hey pose  a  serious  threat  to  public  health.
mong the  ESBL  variants,  CTX-M  -lactamases  have
merged as  the  predominant  ESBL  type  world-
ide [2].  There  are  >130  CTX-M  allelic  variants
hat have  been  described  (http://www.lahey.org/
tudies/other.asp#table1),  of  which,  variant  CTX-
15 is  the  most  common  disseminated  CTX-M
enotype [3,4].  Phylogenetic  analysis  has  shown
hat E.  coli  strains  fall  into  four  main  phyloge-
etic groups  (A,  B1,  B2,  and  D).  Virulent  extra
ntestinal strains  belong  mainly  to  group  B2  and,
o a  lesser  extent,  to  group  D,  whereas  most  com-
ensal  strains  belong  to  groups  A  and  B1  [5].
mong  the  phylo-groups,  it  has  been  observed
hat the  prevalence  of  antimicrobial  resistance  was
igher in  non-B2  group  strains  [6,7].  However,  in
ndia, the  prevalence  of  ESBL  genes  among  various
hylo-groups  has  not  been  adequately  explored.  To
ssess the  relationships  between  the  phylogenetic
ackgrounds  of  strains  carrying  ESBL  genes  to  the
atient’s clinical  outcome,  we  analyzed  a collec-
ion of  ESBL-producing  E.  coli  isolates  involved  in
arious extra-intestinal  infections,  their  resistance
attern  and  effect  on  patient  clinical  outcome.
aterials and methods
articipants and clinical isolates
he  study  was  performed  from  August  2010  to
anuary 2013  on  hospitalized  patients  of  two  ter-
iary care  hospitals  in  Mangalore,  India,  after
btaining permission  from  the  institutional  ethi-
al committee.  Three-hundred  non-repeat  strains
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ented  the  high  prevalence  of  ESBLs  in  E.  coli  isolates,
inant  ESBL  gene  in  the  region,  and  these  isolates  pre-
ensal  phylo-groups.  Thus,  an  appropriate  antibiotic  and
 reduce  the  horizontal  spread  of  ESBL  genes  among  var-
as  in  the  near  future,  the  spread  of  ESBL  producers  may
ds.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
f  E.  coli  were  included  in  the  study.  Details  of
he antibiotics  used  and  the  clinical  outcome  of
hese patients  were  collected.  The  isolates  were
dentiﬁed  using  standard  biochemical  tests  and  the
utomated system  Vitek  2  (bioMerieux)  [8].
ntimicrobial susceptibility testing
ntibiotic  susceptibility  testing  was  performed
sing the  modiﬁed  Kirby-Bauer  disk  diffusion
ethod according  to  CLSI  guidelines  [9].  The
ntibiotic disks  (HiMedia,  Mumbai,  India)  used
ere Ampicillin  (10  g),  Piperacillin  (10  g),
iperacillin +  Tazobactam  (100/10  g),  Ceftriaxone
30 g),  Cefotaxime  (30  g),  Ciproﬂoxacin  (5  g),
orﬂoxacin  (10  g),  Amikacin  (30  g),  Gentamicin
10 g),  Cotrimoxazole  (1.25/23.75  g),  Cefop-
razone + Sulbactam  (75/30  g),  Imepenem  (IPM;
0 g),  Meropenem  (MRP;  10  g)  and  Etrapenem
ETP; 10  g).
hylotyping analysis
hylogenetic  analysis  was  performed  using  triplex
CR-based  methods  as  described  by  Clermont  et  al.
10].  Brieﬂy,  a  combination  of  two  genes  (chuA  and
jaA) and  an  anonymous  DNA  fragment  (TSPE4.C2)
llows  for  the  determination  of  the  main  phyloge-
etic groups  of  E.  coli  (i.e.,  A,  B1,  B2  and  D).
enotypic detection of ESBL encoding genes
 multiplex  PCR  assay  was  performed  to  detect  and
ifferentiate  blaTEM,  blaSHV and  blaCTX-M genes  per
he primers  and  conditions  previously  described,
ith minor  modiﬁcation  [11,12].  To  summarize,  PCR
as performed  in  a ﬁnal  reaction  volume  of  50  l
ontaining  750  Mm  Tris—HCl,  200  mM  (NH4)2SO4,
.5 mM  MgCl2, 0.2  mM  each  of  dNTP,  0.5  M  of
ach primer,  1.5  U  of  Taq  DNA  polymerase  and  5  l
f template  DNA.  An  Eppendorf  thermocycler  was
sed for  ampliﬁcation.  The  program  for  ampliﬁca-
ion included  a step  of  initial  denaturation  at  95 ◦C
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for  3  min  followed  by  30  cycles  of  95 ◦C  for  1  min,
58 ◦C  for  1  min  and  72 ◦C  for  1  min  and  a  ﬁnal  exten-
sion step  at  72 ◦C  for  7  min.  The  PCR  products  were
loaded in  2%  (w/v)  agarose  gel  prepared  in  Tris-
borate—EDTA buffer  at  120  V  for  1  h  and  detected
using ethidium  bromide  staining  after  electrophore-
sis.
Another PCR  assay  was  performed  to  detect  the
blaCTXM-15 variant  of  blaCTX-M gene  per  the  primer
and conditions  previously  described,  with  minor
modiﬁcation  [13]. The  PCR  was  performed  in  a
ﬁnal reaction  volume  of  50  l,  containing  750  Mm
Tris—HCl,  200  mM  (NH4)2SO4,  2.5  mM  MgCl2, 0.2  mM
of each  dNTP,  0.4  M  of  each  primer,  1.5  U  of  Taq
DNA polymerase  and  5  l  of  template  DNA.  An
Eppendorf thermocycler  was  used  for  ampliﬁcation.
The program  for  ampliﬁcation  included  a  step  of  ini-
tial denaturation  at  95◦ C  for  3 min  followed  by  30
cycles of  95◦ C  for  1  min,  50◦ C  for  1  min  and  72◦ C
for 1  min  and  a  ﬁnal  extension  step  at  72◦ C  for
7 min.  The  PCR  products  were  loaded  in  2%  (w/v)
agarose gel  prepared  in  Tris-borate—EDTA  buffer  at
120 V  for  1  h  and  detected  using  ethidium  bromide
staining after  electrophoresis.
Statistical analysisThe  chi-square  test  was  used  to  identify  an
association between  ESBL  carriage,  phylo  group
and the  patient’s  clinical  outcome.  Analysis  was
9
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Table  1  Characterization  of  ESBL  genes  harbouring  E.  coli
Characteristics  of
isolates
No  of  strains  carrying
ESBL  genes  (%)
Phylogroup
A  (n  =  61)  41(67)  
B1  (n  =  27)  22(81.5)  
B2  (n  =  104) 67(64.5)  
D  (n  =  108)  82(76)  
Infection
UTI  (n  =  159)  109(68.5)  
SEPSIS  (n  =  77)  54(70)  
WOUND  (n  =  40)  30(75)  
PNEUMONIA  (n  =  19)  14(73.5)  
IVD  (n  =  3)  3(100)  
MENINGITIS  (n  =  2)  2(100)  
Outcome
IMPROVED  (n  =  202)  141(70)  
RELAPSES  (n  =  55)  39(71)  
EXPIRED  (n  =  33)  26(79)  
LOST  TO  FOLLOW  UP  (n  =  10)  6(60)  
Total  (n  =  300)  212(%)  
# Some strains contained multiple ESBL genes; P value: <0.05*.A.  Chakraborty  et  al.
erformed  using  the  statistical  package  SPSS  ver-
ion 17.0.
esults
 total  of  300  E.  coli  isolates  from  extra-intestinal
ources were  collected.  The  primary  site  of  infec-
ion included  159  (53%)  cases  of  UTI,  77  (25.6%)
ases of  bacteremia,  40  (13.3%)  cases  of  wound
nfection, 19  (6.3%)  cases  of  pneumonia,  3  (1%)
ases  of  intravascular  device  infection  and  2  (0.6%)
ases of  meningitis.  Of  the  300  isolates  tested,  212
70.5%) isolates  carried  ESBL  genes,  either  single  or
ultiple enzymes.  A  total  of  186  (62%)  strains  out
f 300  isolates  were  positive  for  blaCTX-M gene,  41
14%) isolates  were  positive  for  blaTEM and  only  13
4%) isolates  were  positive  for  blaSHV.  Twenty  (7%)
solates  were  positive  for  both  blaTEM and  blaCTX-M,
hereas 6  (2%)  isolates  were  positive  for  blaSHV
nd  blaCTX-M. However,  only  one  isolate  was  posi-
ive for  all  -lactam  genes,  namely  blaTEM,  blaSHV
nd  blaCTX-M genes.
A  996-bp  fragment  was  ampliﬁed  to  detect
laCTX-M15, which  is  the  most  common  subtype  of
laCTXM. In addition,  171  isolates  (approximately
2%) out  of  186  blaCTX-M producers  were  positive
or blaCTXM-15.
When  the  source-wise  distribution  of ESBL  genes
as considered,  109  (69%)  urinary  isolates  were
 isolates  causing  extra-intestinal  infections.
Type of  ESBL  gene  present  among  isolates  (%) #
TEM  SHV  CTX-M  CTX-M15
8(19.50)  3(7)  34*(83)  31(75.5)
5(23)  4(18)  18*(82)  17(77)
12(18)  2(3)  61*(91)  55(82)
16(19.5)  4(5)  73*(89)  68(83)
23(21)  7(6.5)  93*(85)  82(75)
11(20.5)  5(9)  48*(89)  47(87)
4(13)  0  27*(90)  26(87)
2(14)  0  14*(100)  13(93)
0  1(33)  3*(100)  2(67)
1(50)  0  1(50)  1(50)
29(20.5)  9(6)  118*(84)  106(75)
06(15.5)  0  39*(100)  37(95)
06(23)  4(15)  23*(88.5)  22(84.5)
0  0  6(100)  6(100)
41(%)  13(%)  186(%)  171(%)
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Table  2  Resistance  proﬁle  of  the  non-beta  lactum  groups  of  antibiotics  among  the  ESBL  producing  isolates.
No  of  isolates  resistant
to  non  -Lactams
(n  =  300)
No of  isolates
carrying  ESBL
genes
(n  =  212)
No  of  ESBL  producing  isolates  carrying  different  type  of
ESBL  genes*
TEM
n  =  41(%)
SHV
n  =  13(%)
CTXM
n  =  186(%)
CTXM15
n  =  171(%)
Gentamycin  (n  =  138) 125(90.5) 19(15) 7(5.5) 119(95)  110(88)
Ciproﬂoxacin  (n  =  195) 162(83) 24(15) 10(6) 149(92) 137(84.5)
Norﬂoxacin  (n  =  180)  84(47)  14(16.5)  4(5)  76(90.5)  69(82)
Nalidixic  acid  (n  =  139)  110(79)  22(20)  5(4.5)  50(45.5)  82(75)
Amikacin  (n  =  75)  66(88)  11(16.5)  6(9)  62(94)  56(85)
Cotrimoxazole  (n  =  144)  89(62)  19(21)  3(3)  82(92)  73(82)
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ositive  for  ESBL  genes  and  54  (70%)  strains  isolated
rom  blood,  30  (75%)  isolates  from  wound  infec-
ions, 14  (74%)  strains  causing  pneumonia,  3  isolates
rom IVD  and  2  CSF  isolates  were  positive  for  the
SBL gene.  The  source-wise  distribution  of  the  iso-
ates according  to  the  presence  of  TEM,  SHV,  CTXM
nd CTXM-15  genes  are  summarized  in  Table  1.
Using triplex  PCR,  phylogenetic  analysis  of  iso-
ates indicated  that  61  (20%)  isolates  belonged  to
roup A,  27  (9%)  isolates  belonged  to  group  B1,
04 (35%)  isolates  belonged  to  group  B2  and  108
36%) isolates  belonged  to  group  D.  There  was  no
igniﬁcant  correlation  between  the  phylo-groups
virulent and  commensal)  and  ESBL-producing  iso-
ates. The  distribution  of  ESBL  genes  according  to
hylogenetic  groups  is  summarized  in  Table  1.
The results  obtained  from  the  Kirby-Bauer  disk
iffusion  studies  indicated  that,  of  the  300  iso-
ates,  291  (97%)  isolates  were  fully  susceptible  to
rtapenem,  and  similarly,  282  (94%),  276  (92%)  and
67 (89%)  isolates  were  susceptible  to  Meropenem,
mipenem and  Nitrofurantoin,  respectively.  Two-
undred  (67%)  isolates  were  resistant  to  three  or
ore antimicrobial  agents  and  thus  were  consid-
red as  multidrug-resistant  (MDR)  strains.  Among
he isolates,  195  (65%)  isolates  were  resistant
o ciproﬂoxacin,  144  (48%)  isolates  were  co-
rimoxazole-resistant  and  138  (46%)  isolates  were
entamicin-resistant.  Analysis  of  drug-resistance
atterns showed  that  all  ESBL  producers  were  more
requently  co-resistant  to  other  non-beta  lactam
lasses  of  antibiotics.  In  addition,  the  resistance
roﬁle of  the  non-beta  lactam  groups  of  drugs
mong the  ESBL-producing  isolates  is  summarized
n Table  2.
In the  present  study,  the  maximum  number  of
atients  (67%)  were  recovered  with  appropriate
ntibiotic treatment.  Relapses  and  re-infections
ere observed  in  18%  and  11%  of  patients,  respec-
ively, and  the  primary  cause  of  death  was  E.  coli
p
s
b
cnfection.  Distribution  of  ESBL  genes  among  the  out-
ome groups  is  summarized  in  Table  1.
iscussion
n  our  study,  we  observed  a high  rate  of  geno-
ypically ESBL-positive  isolates  (70.5%),  which
ndicated  a  high  prevalence  of  ESBL  producers  in
ur study  compared  to  studies  done  by  Pournaras
t al.  and  Edelstein  et  al.  [14,15].  Our  study  found
laCTX-M to  be  the  most  predominant  type  of  plas-
id among  ESBL  producers  (88%)  and  only  19%  were
laTEM-positive,  and  the  presence  of  the  blaSHV
ype  was  observed  in  very  few  isolates  (2%).  Among
he combinations  of  ESBL  genes  detected,  only
% isolates  carried  both  blaCTX-M and  blaSHV, with
laCTX-M15 being  the  most  predominant  (92%)  sub-
ype among  the  isolates.  In  Western  countries,  the
SBL production  in  Enterobacteriaceae  varied  from
 to  52%,  and  in  other  Asian  countries,  from  10  to
6.5% [16]. Zaniani  et  al.  from  Iran  also  reported
hat 44%  of  their  isolates  were  ESBL-positive,  among
hich 15%  were  positive  for  blaSHV and  21%  were
ositive for  blaTEM [17]. Pournaras  et  al.  reported
n 87%  prevalence  of  blaCTX-M enzyme  among  ESBL
roducers in  a tertiary  care  hospital  of  Greece  [14].
n a multicentric  study  in  Russia  has  been  reported
hat 35.9%  of  their  E.  coli  isolates  were  harbor-
ng blaCTX-M gene  [15]. Brenwald  et  al.  reported
n outbreak  of  blaCTX-M harboring  ESBL  in  the  UK
18]. In  a  nationwide  survey  performed  in  Italy,
laCTX-M-producing  strains  were  reported  by  10  of
he 11  participating  centers,  with  remarkable  vari-
ble rates  between  centers  (1.2—49.5%  of  the  ESBL
roducers)  [19]. In  India,  Goyal  et  al.  used  speciﬁc
rimers  for  blaTEM, blaSHV and  blaCTX-M and  demon-
trated that  82  (75.2%)  of  109  ESBL  isolates  could
e typed  for  one  or  more  genes,  a ﬁnding  that  is
omparable  to  our  study  [20]. Two  or  more  ESBL
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genes  were  present  in  57.3%  of  typeable  isolates.
Moreover, blaCTX-M was  the  most  common  and  was
present either  alone  or  in  combination  with  another
ESBL type  (s).  Their  ﬁnding  supports  the  hypothe-
sis that  blaCTX-M is  emerging  as  the  dominant  ESBL
type in  clinical  isolates.  Furthermore,  blaCTX-M-15
is  known  to  be  an  ESBL  that  has  a  unique  asso-
ciation with  community-onset  E.  coli  infections.
Ensor et  al.  have  shown  that  in  India,  blaCTX-M-15
is  more  prevalent  than  any  other  type  and  it  is
widely  distributed  in  both  North  and  South  India
[21].  They  also  reported  that  the  Indian  popula-
tion represented  a  signiﬁcant  reservoir  and  source
of blaCTX-M-15,  which  is  consistent  with  the  ﬁndings
in our  study.
Our phylogenetic  analysis  of  the  isolates
revealed that  the  presence  of  ESBL  genes  was
slightly higher  in  commensal  E.  coli  strains  (Groups
A and  B1)  compared  to  virulent  strains  (Groups
B2 and  D),  indicating  that  commensal  strains  are
silent carriers  of  such  resistance  genes.  Several
other investigators  from  outside  of  India  have  also
reported  similar  ﬁndings  [22,23].  Our  study  also
revealed  that  the  blaCTXM-15 genes  were  more  or
less equally  distributed  in  commensal  (Groups  A  and
B1) as  well  as  in  virulent  (Group  B2  and  D)  strains.
However, Pitout  et  al.  reported  that  blaCTXM15 was
predominantly higher  in  virulent  strains  and  were
mainly found  in  the  B2  group  [24].
We are  not  the  ﬁrst  to  observe  a  signiﬁcantly
high degree  of  resistance  to  multiple  classes  of
antibiotics  among  ESBL-producing  isolates.  Several
other investigators  have  also  reported  that  ESBL-
producing  organisms  were  frequently  resistant  to
non--lactam  antibiotics,  such  as  ﬂuoroquinolones,
cotrimoxazole  and  aminoglycosides  [24,25].  Only
the carbapenem  group  of  antibiotics,  speciﬁcally
ertapenem,  was  the  most  active  among  all  of  the
antimicrobials  tested.  In  an  analysis  of  an  ESBL
producing strains  with  the  clinical  outcome  of  our
study population,  we  observed  that  70%  of  E.  coli
isolate  patients  who  completely  recovered  were
harboring ESBL  genes.  In  the  case  of  a  relapse  of
infections,  we  found  that  71%  isolates  were  positive
for ESBL  genes.  Interestingly,  in  such  relapse  cases,
all isolates  harbored  blaCTXM genes  and  95%  of  those
isolates were  positive  with  blaCTXM-15. The  pres-
ence of  ESBL  genes  in  E.  coli  isolates  from  expired
cases  was  higher  compared  with  either  improved  or
relapse cases.
In conclusion,  the  present  study  clearly  indicates
that blaCTX-M,  speciﬁcally  blaCTXM-15,  in  ESBL-
producing  E.  coli  was  highly  endemic  in  the  region.
The presence  of  the  blaCTXM gene  among  virulent  as
well as  non-virulent  (commensal)  phylo  groups  sug-
gests that  commensal  and  virulent  isolates  may  actA.  Chakraborty  et  al.
s  a reservoir  of  antibiotic  resistance  genes,  a  ﬁnd-
ng that  is  of  a  major  concern  to  attending  clinicians
nd present  day  treatment  modalities.  An  appropri-
te hospital  antibiotic  policy  and  a  decreased  usage
f antimicrobials  in  poultry  and  agricultural  prod-
cts should  be  practiced  to  control  the  spread  of
esistance  genes;  otherwise,  it may  result  in  thera-
eutic dead  ends  in  the  near  future.
Our study  had  speciﬁc  limitations;  there  are  >130
ariants  of  CTX-M.  We  studied  only  the  CTMX-15
ariant, and  phenotypic  detection  of  ESBL  produc-
ion was  not  performed  in  our  study.  However,  it  is
ifﬁcult to  demonstrate  mortality  solely  attributed
o infection  without  a  proper  study  design  and/or
utopsy  to  provide  evidence  that  these  patients  had
ome underlying  conditions.
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